Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus has flown under the radar, but the numbers tell…
Buy
59
AUTL Quote, Financials, Valuation and Earnings
Last price:
$1.53
Seasonality move
:
-0.61%
Day range:
$1.49 - $1.54
52-week range:
$1.11 - $5.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.10x
Volume:
1.2M
Avg. volume:
2.3M
1-year change:
-60.21%
Market cap:
$409.9M
Revenue:
$10.1M
EPS (TTM):
-$0.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
$2M | -$0.25 | -80.39% | -10.73% | $9.97 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -91.39% | -8.33% | $1.58 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group PLC
|
$15.9M | -$0.01 | -100% | -87.66% | $7.60 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$54.8M | -$0.03 | -- | -99.24% | $94.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
$1.54 | $9.97 | $409.9M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.28 | $1.58 | $74.2M | -- | $0.00 | 0% | 0.40x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.15 | $17.94 | $2.9M | -- | $0.00 | 0% | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
$2.24 | $7.60 | $356.2M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.04 | $104.00 | $230.2K | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$75.06 | $94.10 | $6.4B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
-- | 1.803 | -- | 8.74x |
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.631 | 50.03% | 1.57x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.357 | -- | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.393 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -0.390 | -- | -- |
|
VRNA
Verona Pharma PLC
|
51.62% | 0.242 | 4.47% | 8.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$11M | -- | -- | -- | -$8.6M |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$72.8M | -$10.3M | -51.07% | -85.84% | -8.34% | -$12.1M |
Autolus Therapeutics PLC vs. Competitors
-
Which has Higher Returns AUTL or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -781.13% compared to Autolus Therapeutics PLC's net margin of -653.18%. Autolus Therapeutics PLC's return on equity of -49.92% beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M -
What do Analysts Say About AUTL or ADAP?
Autolus Therapeutics PLC has a consensus price target of $9.97, signalling upside risk potential of 547.19%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 462.75%. Given that Autolus Therapeutics PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 0 0 ADAPAdaptimmune Therapeutics PLC3 3 0 -
Is AUTL or ADAP More Risky?
Autolus Therapeutics PLC has a beta of 1.767, which suggesting that the stock is 76.723% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.
-
Which is a Better Dividend Stock AUTL or ADAP?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or ADAP?
Autolus Therapeutics PLC quarterly revenues are $9M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Autolus Therapeutics PLC's net income of -$70.2M is lower than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus 0.40x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M
-
Which has Higher Returns AUTL or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -781.13% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -49.92% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About AUTL or BDRX?
Autolus Therapeutics PLC has a consensus price target of $9.97, signalling upside risk potential of 547.19%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1460.34%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is AUTL or BDRX More Risky?
Autolus Therapeutics PLC has a beta of 1.767, which suggesting that the stock is 76.723% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.
-
Which is a Better Dividend Stock AUTL or BDRX?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or BDRX?
Autolus Therapeutics PLC quarterly revenues are $9M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$70.2M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus 1.20x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M BDRXBiodexa Pharmaceuticals PLC1.20x -- -- --
-
Which has Higher Returns AUTL or MREO?
Mereo BioPharma Group PLC has a net margin of -781.13% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -49.92% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About AUTL or MREO?
Autolus Therapeutics PLC has a consensus price target of $9.97, signalling upside risk potential of 547.19%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.60 which suggests that it could grow by 239.06%. Given that Autolus Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Autolus Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 0 0 MREOMereo BioPharma Group PLC6 0 0 -
Is AUTL or MREO More Risky?
Autolus Therapeutics PLC has a beta of 1.767, which suggesting that the stock is 76.723% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.542%.
-
Which is a Better Dividend Stock AUTL or MREO?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or MREO?
Autolus Therapeutics PLC quarterly revenues are $9M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$70.2M is lower than Mereo BioPharma Group PLC's net income of -$12.9M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M MREOMereo BioPharma Group PLC-- -- -- -$12.9M
-
Which has Higher Returns AUTL or NCNA?
NuCana PLC has a net margin of -781.13% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -49.92% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About AUTL or NCNA?
Autolus Therapeutics PLC has a consensus price target of $9.97, signalling upside risk potential of 547.19%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 273584.21%. Given that NuCana PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe NuCana PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 0 0 NCNANuCana PLC0 1 0 -
Is AUTL or NCNA More Risky?
Autolus Therapeutics PLC has a beta of 1.767, which suggesting that the stock is 76.723% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.
-
Which is a Better Dividend Stock AUTL or NCNA?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or NCNA?
Autolus Therapeutics PLC quarterly revenues are $9M, which are larger than NuCana PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$70.2M is lower than NuCana PLC's net income of -$836.1K. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns AUTL or VRNA?
Verona Pharma PLC has a net margin of -781.13% compared to Autolus Therapeutics PLC's net margin of -21.4%. Autolus Therapeutics PLC's return on equity of -49.92% beat Verona Pharma PLC's return on equity of -85.84%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M VRNAVerona Pharma PLC95.53% -$0.16 $468.3M -
What do Analysts Say About AUTL or VRNA?
Autolus Therapeutics PLC has a consensus price target of $9.97, signalling upside risk potential of 547.19%. On the other hand Verona Pharma PLC has an analysts' consensus of $94.10 which suggests that it could grow by 25.37%. Given that Autolus Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Autolus Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 0 0 VRNAVerona Pharma PLC7 0 0 -
Is AUTL or VRNA More Risky?
Autolus Therapeutics PLC has a beta of 1.767, which suggesting that the stock is 76.723% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.206, suggesting its less volatile than the S&P 500 by 79.434%.
-
Which is a Better Dividend Stock AUTL or VRNA?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or VRNA?
Autolus Therapeutics PLC quarterly revenues are $9M, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. Autolus Therapeutics PLC's net income of -$70.2M is lower than Verona Pharma PLC's net income of -$16.3M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M VRNAVerona Pharma PLC-- -- $76.3M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Celsius Stock Forecast: Will Earnings Spark Another Surge?
Energy drink seller Celsius Holdings, Inc. (NASDAQ:CELH) has reported somewhat…
Will DigitalOcean Stock Bounce Back?
DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
60
MRUS alert for May 24
Merus NV [MRUS] is up 32.55% over the past day.
Buy
57
RGC alert for May 24
Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.
Buy
90
OKLO alert for May 24
Oklo [OKLO] is up 23.11% over the past day.
